Drug Profile
Tonabersat - InflammX
Alternative Names: SB-220453; USL-260; Xiflam™Latest Information Update: 20 Feb 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer InflammX; Proximagen
- Class Analgesics; Antiepileptic drugs; Antimigraines; Benzamides; Benzopyrans; Eye disorder therapies; Small molecules
- Mechanism of Action Connexin 43 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetic macular oedema; Diabetic nephropathies; Dry macular degeneration
- Discontinued Epilepsy; Migraine; Neuropathic pain
Most Recent Events
- 14 Feb 2023 Jaeb Center for Health Research plans a phase II trial for Diabetic macular oedema (In adults, In the elderly) in 2023 (PO) (NCT05727891)
- 07 Oct 2022 Discontinued - Phase-I for Epilepsy in United Kingdom (PO) before October 2022
- 30 Sep 2022 Preclinical trials in Diabetic macular oedema in USA (PO) before September 2022